PD mTOR Signaling Modulation Companies

Migration, Crosslink

📖

PD mTOR Signaling Modulation Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-mtor-signaling-modulat

📖 Wiki Page

company977 wordssynced 2026-04-02

Overview

flowchart TD companies_pd_mtor_signaling_mo["PD mTOR Signaling Modulation Companies"] companies_pd_mtor_signaling_mo["category"] companies_pd_mtor_signaling_mo -->|"related to"| companies_pd_mtor_signaling_mo style companies_pd_mtor_signaling_mo fill:#81c784,stroke:#333,color:#000 companies_pd_mtor_signaling_mo["covers"] companies_pd_mtor_signaling_mo -->|"related to"| companies_pd_mtor_signaling_mo style companies_pd_mtor_signaling_mo fill:#81c784,stroke:#333,color:#000 companies_pd_mtor_signaling_mo["biotechnology"] companies_pd_mtor_signaling_mo -->|"related to"| companies_pd_mtor_signaling_mo style companies_pd_mtor_signaling_mo fill:#81c784,stroke:#333,color:#000 companies_pd_mtor_signaling_mo["pharmaceutical"] companies_pd_mtor_signaling_mo -->|"related to"| companies_pd_mtor_signaling_mo style companies_pd_mtor_signaling_mo fill:#81c784,stroke:#333,color:#000 style companies_pd_mtor_signaling_mo fill:#4fc3f7,stroke:#333,color:#000

This category covers biotechnology and pharmaceutical companies developing mTOR (mammalian target of rapamycin) signaling modulators for Parkinson's disease. These approaches target the dysregulated mTOR pathway that contributes to autophagy impairment, alpha-synuclein aggregation, and neuronal dysfunction in PD.

...

Overview

Mermaid diagram (expand to render)

This category covers biotechnology and pharmaceutical companies developing mTOR (mammalian target of rapamycin) signaling modulators for Parkinson's disease. These approaches target the dysregulated mTOR pathway that contributes to autophagy impairment, alpha-synuclein aggregation, and neuronal dysfunction in PD.

The mTOR pathway is a central regulator of cellular growth, metabolism, and protein homeostasis. In Parkinson's disease, mTOR signaling is often dysregulated, leading to impaired autophagy and accumulation of toxic protein aggregates. Therapeutic strategies target both direct mTOR inhibition and mTOR-independent pathways that restore lysosomal function.

Key Companies

mTOR Inhibitors (Rapalogs and Derivatives)

Servier

Focus: mTORC1/2 dual inhibition
Lead Candidate: Servier 1
Indication: Amyotrophic Lateral Sclerosis (ALS) - with relevance to PD
Stage: Phase 1/2
Mechanism: Dual mTORC1/2 inhibition promotes autophagy and clears protein aggregates
Page: [Servier](/companies/servier)

Servier's mTORC1/2 inhibitor program addresses ALS but represents a broader mTOR modulation strategy applicable to Parkinson's disease. The company's neuroscience division focuses on neurodegenerative diseases with high unmet need.

mTOR-Independent Autophagy Enhancers

Z-index Pharma

Focus: mTOR-independent autophagy inducers
Lead Candidate: ZX-42
Indication: Parkinson's Disease, Alzheimer's Disease
Stage: IND-enabling
Mechanism: Promotes autophagy through Beclin-1 complex modulation, TFEB activation via mTOR-independent pathways, and VPS34 complex enhancement
Page: [Z-index Pharma](/companies/z-index-pharma)

Z-index Pharma's approach addresses a key limitation of direct mTOR inhibition—metabolic side effects—by targeting downstream pathways that achieve autophagy enhancement without broad mTOR suppression[@sarkar2011].

TFEB Activators (mTOR-Associated)

TFEB (Transcription Factor EB) is the master regulator of lysosomal biogenesis and is downstream of mTOR signaling. Several companies target TFEB to achieve lysosomal enhancement:

AtlasX Bio

Focus: Next-generation TFEB activators
Lead Candidate: ATL-1001
Indication: Parkinson's Disease, Alzheimer's Disease
Stage: Phase I planned (2026)
Mechanism: mTOR-independent TFEB activation via calcineurin pathway, enhanced brain penetration
Page: [AtlasX Bio](/companies/atlasx-bio)

Lyterian Therapeutics

Focus: mTOR-independent TFEB activation
Lead Candidate: LT-002
Indication: Parkinson's Disease
Stage: Preclinical
Mechanism: Direct TFEB nuclear translocation without mTOR inhibition
Page: [Lyterian Therapeutics](/companies/lyterian-therapeutics)

Heqix Therapeutics

Focus: Autophagy induction through mTOR modulation
Lead Candidate: HQX-001
Indication: Parkinson's Disease
Stage: Discovery
Mechanism: mTOR modulators to enhance autophagy and lysosomal function
Page: [Heqix Therapeutics](/companies/heqix-therapeutics)

Adjacent Approaches (Autophagy/Lysosomal)

Retro Biosciences

Focus: Macroautophagy enhancement
Lead Candidate: RB-001
Indication: Alzheimer's Disease (Phase 1), Parkinson's Disease (preclinical)
Stage: Phase 1
Mechanism: Small molecule enhancers of macroautophagy
Page: [Retro Biosciences](/companies/retro-biosciences)

Lysoway Therapeutics

Focus: Lysosomal ion channel modulators
Lead Candidates: LY-001 (TRPML1 agonist), LY-002 (TMEM175 agonist)
Indication: Parkinson's Disease, Alzheimer's Disease
Stage: Preclinical/Discovery
Mechanism: Agonists of lysosomal cation channels to enhance autophagy-lysosomal function through calcium signaling
Page: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

Pipeline Summary

| Company | Drug | Mechanism | Phase | Indication |
|---------|------|-----------|-------|-----------|
| Servier | Servier 1 | mTORC1/2 inhibitor | Phase 1/2 | ALS |
| Z-index Pharma | ZX-42 | mTOR-independent autophagy | IND-enabling | PD/AD |
| AtlasX Bio | ATL-1001 | TFEB activator (mTOR-independent) | Phase I planned | PD/AD |
| Lyterian Therapeutics | LT-002 | TFEB activation | Preclinical | PD |
| Heqix Therapeutics | HQX-001 | mTOR modulation | Discovery | PD |
| Retro Biosciences | RB-001 | Autophagy enhancer | Phase 1 | AD/PD |
| Lysoway Therapeutics | LY-001 | TRPML1 agonist | Preclinical | PD/AD |

Therapeutic Mechanisms

mTOR Inhibition Approaches

Direct mTOR Inhibition (Rapalogs): Rapamycin, Torin 1—blocks mTORC1 to release TFEB and induce autophagy. Limitations include immunosuppression, metabolic side effects, and poor brain penetration.

mTORC1/2 Dual Inhibition: Servier 1—targets both complexes for more complete pathway suppression. Broader effect but may have increased side effect profile.

mTORC2-Selective Modulation: Emerging approach targeting mTORC2 for neuronal survival pathways without immunosuppression.

mTOR-Independent Approaches

TFEB Activation: Direct activation of TFEB through calcineurin or other phosphatases, bypassing mTOR entirely. Achieves lysosomal biogenesis without metabolic disruption.

Beclin-1 Complex Modulation: Enhancing Beclin-1 phosphorylation to promote ATG14L recruitment and autophagosome nucleation without mTOR involvement.

VPS34 Enhancement: Increasing class III PI3K activity to promote autophagosome formation through parallel pathways.

Lysosomal Calcium Channel Modulation: TRPML1 and TMEM175 agonists enhance lysosomal calcium signaling, which intersects with TFEB pathway activation.

Scientific Rationale

mTOR Dysregulation in PD

Multiple studies have documented mTOR pathway dysregulation in Parkinson's disease[@mtor2023][@mtor2023a]:

Alpha-synuclein aggregation: Impaired autophagy due to mTOR overactivity prevents clearance of toxic aggregates
Mitochondrial dysfunction: mTOR regulates mitochondrial quality control through PINK1/Parkin pathways
Neuroinflammation: mTOR signaling influences microglial activation and inflammatory responses
Genetic risk factors: LRRK2 mutations (common in familial PD) interact with mTORC1 signaling

TFEB as Downstream Target

TFEB is a transcription factor that controls the CLEAR (Coordinated Lysosomal Expression and Regulation) network[@tfeb2022][@martini2021][@zhang2022]:

Regulates over 470 genes involved in lysosomal function and autophagy
Under normal conditions, mTORC1 phosphorylates TFEB, keeping it sequestered in the cytoplasm
In PD, dysregulated mTOR keeps TFEB inactive, impairing cellular clearance
Activating TFEB can restore lysosomal function without broad mTOR inhibition

[mTOR Signaling in Parkinson's Disease](/mechanisms/mtor-signaling-parkinsons) — Mechanism page
[TFEB Signaling in Neurodegeneration](/mechanisms/tfeb-signaling-neurodegeneration) — Related pathway
[PD TFEB Activator Companies](/companies/pd-tfeb-activator-companies) — Related category
[PD Lysosomal and Autophagy Companies](/companies/pd-lysosomal-autophagy-companies) — Related category

[mTOR](/genes/mtor) — Master regulator kinase
[TFEB](/proteins/tfeb-protein) — Transcription factor
[Alpha-synuclein](/proteins/alpha-synuclein) — Target for clearance
[LRRK2](/genes/lrrk2) — PD risk gene that modulates mTOR
[GBA](/genes/gba) — PD risk gene affecting lysosomal function
[PINK1](/genes/pink1) — Mitochondrial quality control
[Parkin](/genes/parkin) — Mitophagy regulator

References

[mTOR Signaling in Parkinson's Disease Mechanism](/mechanisms/mtor-signaling-parkinsons)

[Liu K et al., mTOR in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37217609/)

[Pong K et al., mTOR inhibition for Parkinson's disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37189752/)

[Sarkar S et al., Rapamycin and mTOR-independent autophagy inducers (2011)](https://pubmed.ncbi.nlm.nih.gov/21490435/)

[Zhang X et al., TFEB and lysosomal biogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35222900/)

[Martini-Stoica H et al., TFEB coordinates autophagic lysosomal regeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34594067/)

[Zhang Y et al., TFEB drives lysosomal biogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35820714/)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD mTOR Signaling Modulation Companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-pd-mtor-signaling-modulation-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-pd-mtor-signaling-modulation-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-37376ccced37
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-mtor-signaling-modulation-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

31

Outgoing

34

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PD mTOR Signaling Modulation Companies

Overview

Overview

Key Companies

mTOR Inhibitors (Rapalogs and Derivatives)

Servier

mTOR-Independent Autophagy Enhancers

Z-index Pharma

TFEB Activators (mTOR-Associated)

AtlasX Bio

Lyterian Therapeutics

Heqix Therapeutics

Adjacent Approaches (Autophagy/Lysosomal)

Retro Biosciences

Lysoway Therapeutics

Pipeline Summary

Therapeutic Mechanisms

mTOR Inhibition Approaches

mTOR-Independent Approaches

Scientific Rationale

mTOR Dysregulation in PD

TFEB as Downstream Target

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

PD mTOR Signaling Modulation Companies

Overview

Overview

Key Companies

mTOR Inhibitors (Rapalogs and Derivatives)

Servier

mTOR-Independent Autophagy Enhancers

Z-index Pharma

TFEB Activators (mTOR-Associated)

AtlasX Bio

Lyterian Therapeutics

Heqix Therapeutics

Adjacent Approaches (Autophagy/Lysosomal)

Retro Biosciences

Lysoway Therapeutics

Pipeline Summary

Therapeutic Mechanisms

mTOR Inhibition Approaches

mTOR-Independent Approaches

Scientific Rationale

mTOR Dysregulation in PD

TFEB as Downstream Target

Related Mechanisms

Related Genes and Proteins

References

Pathway Diagram

💬 Discussion